Scienture Holdings (SCNX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$821,315.00

Revenue (quarter)

$343,639.00

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$720,438.00

Gross margin

87.72%

Net income (trailing twelve months)

−$38.0M

Net income (quarter)

−$2.8M

Net income growth (year over year)

+58.00%

Net margin

−4620.92%

Return on equity

−53.47%

EPS (trailing twelve months)

−$5.87

Book value per share

$39.03

P/E (trailing twelve months)

—

Price to book

0.09

Debt to assets

26.94%

Payout ratio

129.60%

Dividend yield

4.76%

Company profile

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.

• Is Scienture Holdings (SCNX) profitable?

  No. Scienture Holdings reported a net loss of $38.0M over the trailing twelve months.

• How much revenue does Scienture Holdings (SCNX) make?

  Scienture Holdings generated $821,315.00 in revenue over the trailing twelve months.

• How do I buy stock in Scienture Holdings (SCNX)?

  SCNX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.